Paliperidone Tablet, Extended Release
NDC Package 31722-320-30
Package Information
Paliperidone tablets is paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see Clinical Studies (14.1)].The efficacy of paliperidone in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. This formulation utilizes a tablet, extended release delivery system. Marketed by Camber Pharmaceuticals, Inc, this product is identified by NDC 31722-320 and is authorized under FDA application ANDA216174.
Identification & Billing
- RxCUI: 672567 - paliperidone 3 MG 24HR Extended Release Oral Tablet
- RxCUI: 672567 - 24 HR paliperidone 3 MG Extended Release Oral Tablet
- RxCUI: 672567 - paliperidone 3 MG 24 HR Extended Release Oral Tablet
- RxCUI: 672569 - paliperidone 6 MG 24HR Extended Release Oral Tablet
- RxCUI: 672569 - 24 HR paliperidone 6 MG Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 31722 - Camber Pharmaceuticals, Inc
- 31722-320 - Paliperidone
- 31722-320-30 - 30 TABLET, EXTENDED RELEASE in 1 BOTTLE
- 31722-320 - Paliperidone
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 31722-320-30 identifies a specific commercial package of 30 tablet, extended release in 1 bottle of Paliperidone, a human prescription drug labeled by Camber Pharmaceuticals, Inc. This tablet, extended release is formulated for oral use and contains paliperidone as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Camber Pharmaceuticals, Inc on August 23, 2023. The current certification is valid through December 31, 2027.
How is this Camber Pharmaceuticals, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 31722032030. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.